EMVision Medical Devices (ASX:EMV) has strengthened its growth trajectory with firm commitments for a $12 million capital raising, receiving strong backing from institutional, sophisticated, and professional investors.

BlinkLab (ASX:BB1) has announced the addition of the Thompson Center for Autism and Neurodevelopment at the University of Missouri as the sixth US clinical site for its pivotal FDA 510(k) diagnostic trial.

CSL (ASX:CSL) has announced a deal with Dutch biotech VarmX to advance a new therapy designed to restore blood clotting in patients taking Factor Xa (FXa) inhibitors, a widely prescribed class of anticoagulants.

Australian digital health company Adherium (ASX:ADR) has reported striking interim results from a large-scale US study showing its Hailie Smartinhaler can transform outcomes for people living with chronic respiratory conditions such as asthma and COPD.

Australian biotech Cleo Diagnostics (ASX:COV) has taken a step forward in its bid to bring an innovative ovarian cancer triage test to market, following positive guidance from the US Food and Drug Administration.

AVITA Medical (ASX:AVH) has achieved a significant milestone with the granting of the CE Mark under the European Union Medical Device Regulation for its next-generation wound care device, RECELL GO.

Actinogen Medical (ASX:ACW) has reached a critical regulatory milestone in its bid to bring a novel Alzheimer’s treatment to market, securing agreement with the US FDA on the path forward for its lead therapy, Xanamem (emestedastat).

Australian company Alterity Therapeutics (ASX:ATH) has announced encouraging results from its Phase 2 trial of ATH434, a first-in-class therapy for Multiple System Atrophy.

Australian biotech HaemaLogiX has been recognised as a rising leader in advanced cancer therapies, taking home the award for 'Most Promising CAR-T Pipeline in APAC' at the Asia Pacific CGT Excellence Awards 2025, held in Singapore.

Australian biotechnology company Cartherics has been recognised as a regional leader in cell and gene therapy, winning the award for ‘Most Promising iPSC Therapy Pipeline in APAC’ at the Asia Pacific Cell and Gene Therapy Excellence Awards 2025 in Singapore.

Arovella Therapeutics (ASX:ALA) has reinforced its commitment to sustainable business practices with the release of its fourth Environmental, Social, and Governance Report, outlining progress in governance, environmental responsibility, social impact, and long-term value creation.

Lumos Diagnostics (ASX:LDX) has broadened access to its flagship rapid diagnostic test, FebriDx, through a new distribution agreement with Amtech Medical, part of the Australasian healthcare alliance YesGroup.

Actinogen Medical (ASX:ACW) has launched a new Investor Hub, designed to strengthen engagement with shareholders as the company moves closer to pivotal milestones in its late-stage Alzheimer’s disease trial.

Alterity Therapeutics (ASX:ATH) has secured $20 million in new funding to accelerate the development of its lead drug candidate ATH434, a potential disease-modifying therapy for multiple system atrophy (MSA), a rare and devastating neurodegenerative disorder.

In its September 2025 shareholder letter, CLINUVEL Chairman Professor Jeffrey V. Rosenfeld has painted a picture of a company that has not only delivered financial stability but also carved out a rare position as a profitable, dividend-paying biotech with no debt and a growing cash reserve.

A University of Queensland PhD student is pioneering the use of sponge-like gold particles to make ovarian cancer diagnosis more accurate, less invasive, and potentially accessible for women in remote communities.

A world-leading Australian virologist has been recognised for transforming the way infectious diseases are detected and understood.